Retatrutide
A triple GLP-1/GIP/glucagon receptor agonist representing the next generation of incretin-based research compounds for metabolic studies.
Mechanism of Action
Retatrutide simultaneously activates three receptors: GLP-1, GIP, and glucagon. The GLP-1 and GIP components enhance insulin secretion and suppress appetite, while the glucagon receptor activation increases energy expenditure, hepatic lipid oxidation, and thermogenesis. This triple agonism produces synergistic metabolic effects beyond what dual agonists achieve.
Key Published Studies
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frias JP, et al. — New England Journal of Medicine (2023)
At the highest dose (12 mg), retatrutide produced a mean body weight reduction of 24.2% at 48 weeks, with 26% of participants achieving over 30% weight loss.
Retatrutide Phase 2 Trial in Type 2 Diabetes
Rosenstock J, Frias JP, Jastreboff AM, et al. — The Lancet (2023)
Retatrutide reduced HbA1c by up to 2.02% and body weight by up to 16.94% at 36 weeks in patients with type 2 diabetes.
Dosage Range
Phase 2 research protocols tested escalating doses from 1 mg to 12 mg once weekly via subcutaneous injection.
Reconstitution
Reconstitute lyophilized powder with bacteriostatic water. For a 10 mg vial, add 1 mL BAC water for a 10 mg/mL concentration.
Storage
Store lyophilized powder at -20C to 4C. Reconstituted solution should be refrigerated at 2-8C and used within 28 days.
Half-Life
Approximately 6 days (144 hours), supporting once-weekly dosing protocols.
Related Products
For Research Use Only. The information on this page is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. All products sold by PrestigePeptides are strictly for laboratory research use and are not intended for human or veterinary consumption.
Ready to start your research?